Astec Lifesciences receives ratings action from ICRA

Astec Lifesciences announced that ICRA has reaffirmed/ assigned the long-term rating of [ICRA]AA- (pronounced 'ICRA double A minus') and the short term rating of [ICRA]A1+ (pronounced 'ICRA A one plus') for the Rs. 839 crore (enhanced from Rs.574 crore) Fund Based and Non-Fund Based facilities of the Company. Further, ICRA has revised the outlook on the long-term rating from 'Stable' to 'Positive'
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jun 25 2022 | 10:43 AM IST
